admin

July 2, 2019

Integral Molecular Presents Data on Monoclonal Antibodies (MAbs) Against SLC2A4 (GLUT4), a Critical Target for Diabetes

PHILADELPHIA -(PR NEWSWIRE)- Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, recently presented data at the American Diabetes Association’s Annual Meeting on […]
May 28, 2019

Integral Molecular Reaches Milestone in Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

PHILADELPHIA -(PR Newswire)- Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, today announced that it has successfully reached the first milestone in […]
April 16, 2019

Integral Molecular Doubles Antibody Characterization Capacity Within Philadelphia’s Science Center

PHILADELPHIA-(PR NEWSWIRE)-Integral Molecular, the industry leader in membrane protein solutions, today announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and […]
March 26, 2019

Integral Molecular to Present Claudin 6 MAbs, a Therapeutic Asset for Solid Tumors, at Annual AACR Conference

PHILADELPHIA–Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, will showcase updated data on its discovery of highly specific Claudin 6 MAbs at […]
January 7, 2019

Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

PHILADELPHIA–(PR NEWSWIRE)–Integral Molecular, the industry leader in membrane protein solutions, today announced that it has entered into a collaboration to discover new therapeutic targets in immuno-oncology […]
January 3, 2019

Integral Molecular Announces Antibody Discovery Collaboration with Ono Pharmaceutical

PHILADELPHIA–(PR NEWSWIRE)–Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against multipass membrane proteins, and Ono Pharmaceutical Co., Ltd. today announced that they […]
December 4, 2018

Integral Molecular’s Therapeutic MAbs Against CB1 to Treat NASH Enter New Development Phase Following $1.4M NIH Award

PHILADELPHIA–(PR NEWSWIRE)–Integral Molecular, the industry leader in antibody discovery against multipass membrane proteins, was awarded $1.4M by the NIH to develop its lead antibodies against cannabinoid […]
November 1, 2018

Integral Molecular Awarded NIH Grant to Discover Neuroimmune Drug Targets in Alzheimer’s Disease

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research (SBIR) grant from the NIH to initiate a target […]
September 18, 2018

Integral Molecular Partners with Merus to Discover Novel Therapeutic Monoclonal Antibodies

PHILADELPHIA – (BUSINESS WIRE) – Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against membrane proteins, and Merus N.V. (Nasdaq:MRUS), a clinical-stage […]